TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy ORR is remarkably high in patients with no prior CAR-T or bispecific therapies (84%) as well as in patients who had received prior T cell- targeted therapies, prior BCMA-targeted therapies, or were refractory to anti-CD38 therapy (range: 71–73%) Safety profile continues to be favorable, with the majority of patients remaining on treatme

– PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population – – FDA premarket approval submission is underway, with completion anticipated mid-2025 – BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC stu

The new show dives into real, raw conversations with the changemakers transforming patient engagement, access, and innovation in clinical research. REDWOOD CITY, Calif., June 2, 2025 /PRNewswire/ -- Clinical research continues to evolve, driven by the empowerment of many voices. Today, Leapcure, a global leader in patient engagement for clinical trials launches its original podcast, Leap Together. Hosted by Leapcure CEO, Zach Gobst, Leap Together explores the stories behind clinical research i

BOULDER, Colo., Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological mal

Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology For U.S. media and investors only DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from th

Ameet Patel, MD Joins Statewide Practice With Expertise in Cellular Therapy and Bone Marrow Transplant FORT MYERS, Fla., June 2, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that cellular therapy expert and bone marrow transplant specialist Ameet Patel, MD has joined the statewide practice. Dr. Patel is providing care to patients in Pinellas County—at FCS St. Petersburg – St. Anthony's, 1201 5th Ave. N., Ste 505, St. Petersburg, FL 33705

New investment helps to ensure patients can access high-quality and reproducible testing across labs worldwide NEW YORK, June 2, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced an investment of up to $2M to expand a quality control program for blood and CSF biomarkers, titled the University of Gothenburg Quality Control Program supported by the Diagnostics Accelerator (DxA) and Global Biomarker Standardization Consortium (GBSC). The program, led by global Al

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiat

VANCOUVER, BC, June 2, 2025 /PRNewswire/ - As new U.S. tariffs hit medical devices and equipment, raw materials, and essential components, iData Research warns of significant cost escalation and supply disruption across the MedTech sector. A recent U.S. court decision blocking the bulk of the proposed tariffs has only added further uncertainty, leaving manufacturers and suppliers navigating shifting trade policies with little clarity. With import duties potentially reaching up to 145%, and the

NASHVILLE, Tenn. and SAN ANTONIO, June 2, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform empowering independent oncology practices, and The START Center for Cancer Care, a physician-owned oncology practice with 44 providers treating patients at six clinics, have finalized a partnership agreement that will enhance the delivery of cancer care services across the San Antonio region. Continue Reading The START Center for Cancer Care has 37 physicians, seven advanced practice pro